NCT03149003: A trial that was reported late by Sumitomo Pharma America, Inc.
This trial has reported, although it was 70 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03149003 |
|---|---|
| Title | A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 8, 2017 |
| Completion date | Aug. 30, 2021 |
| Required reporting date | Aug. 30, 2022, midnight |
| Actual reporting date | Nov. 8, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 70 |